HealthcareServices

Humira Biosimilar Market Outlook 2026–2035: Growth Drivers and Industry Forecast

February 25, 2026February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the humira biosimilar market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Humira Biosimilar Market?

The Humira biosimilar market has seen considerable growth in recent times. It is anticipated to increase from $3.67 billion in 2025 to $4.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.3%. The expansion observed historically can be attributed to several factors, including the patent expiry of Humira, the high expenses linked to branded biologics, a rising incidence of autoimmune diseases, regulatory encouragement for biosimilar approvals, and pressure from payers to reduce expenditures on biologic drugs.

The humira biosimilar market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $6.53 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.2%. Key factors driving this expansion during the projection period include the broader integration of biosimilars into clinical settings, enhanced reimbursement options for these products, a rise in physician trust regarding biosimilar effectiveness, the increase in approvals for interchangeable biosimilars, and new initiatives aimed at improving patient access to cost-effective biologics. Significant trends anticipated within this forecast timeframe encompass the expanding use of adalimumab biosimilars for various autoimmune conditions, a heightened emphasis on managing costs in biologic treatments, greater acceptance of interchangeable biosimilars among healthcare professionals, an increasing need for high-concentration and citrate-free versions, and growing competitive pressure among companies producing biosimilars.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp

Which Drivers Are Supporting The Rise Of The Humira Biosimilar Market?

The expanding incidence of autoimmune conditions is anticipated to fuel the expansion of the humira biosimilar market in the future. Autoimmune diseases manifest when the immune system erroneously targets and assaults the body’s healthy cells, tissues, or organs. The rising occurrence of these diseases is associated with environmental contamination, which disturbs the immune system and increases the likelihood of autoimmune responses. Humira biosimilars function by inhibiting tumor necrosis factor (TNF), a protein responsible for inflammation in autoimmune ailments. This mechanism aids in diminishing immune responses, thereby easing symptoms and safeguarding healthy tissues from harm. For instance, in August 2024, data from Public Health Scotland, a national organization based in Scotland, indicated that the Scottish Multiple Sclerosis Register (SMSR) registered 455 new MS patients in 2023. Consequently, the rising frequency of autoimmune disorders is a key factor propelling the development of the humira biosimilar market.

What Segments Are Identified Within The Structure Of The Humira Biosimilar Market?

The humira biosimilar market covered in this report is segmented –

1) By Product Type: Adalimumab Biosimilars, High-Concentration Adalimumab Biosimilars, Citrate-Free Adalimumab Biosimilars

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

3) By Application: Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Other Applications

Subsegments:

1) By Adalimumab Biosimilars: Citrate-Containing, Standard-Concentration Formulations, Citrate-Free, Standard-Concentration Formulations

2) By High-Concentration Adalimumab Biosimilars: Citrate-Containing High-Concentration Formulations, Citrate-Free High-Concentration Formulations

3) By Citrate-Free Adalimumab Biosimilars: Standard-Concentration Citrate-Free Formulations, High-Concentration Citrate-Free Formulations

Which Trends Are Influencing The Performance And Direction Of The Humira Biosimilar Market?

Key enterprises operating in the humira biosimilar market are prioritizing the development of advanced products, including tumor necrosis factor (TNF) blockers, to deliver more cost-effective solutions for autoimmune disease management. Tumor necrosis factor (TNF) blockers are biological drugs that suppress the activity of TNF, a crucial protein involved in promoting inflammation. For instance, in July 2023, Organon & Co., a pharmaceutical firm based in the U.S., partnered with Samsung Bioepis Co., Ltd., a South Korea-based biotech firm, to release HADLIMA, a biosimilar to Humira. HADLIMA is provided in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) presentations, matching the choices offered by the original Humira, and aims to improve patient access and affordability. The product is marketed at a considerable discount, approximately 85% lower than Humira’s list price, and includes various support programs for patients. This launch, which was enabled by a global settlement allowing U.S. supply, signifies a major accomplishment in expanding treatment options for chronic autoimmune diseases within the U.S.

Which Key Market Players Are Investing In Expansion And Innovation Within The Humira Biosimilar Market?

Major companies operating in the humira biosimilar market are Amgen Inc., Pfizer Inc., Samsung Biologics, Biocon Limited, Celltrion Inc., Boehringer Ingelheim GmbH, Sandoz Group AG, Fresenius Kabi AG, Alvotech, Coherus BioSciences Inc., Zydus Lifesciences Ltd., Hetero Drugs Ltd., LG Chem Ltd., Torrent Pharmaceuticals Ltd., Fujifilm Holdings Corporation, Teva Pharmaceutical Industries Ltd., Merck KGaA, Organon & Co., Cipla Limited, Dr. Reddy’s Laboratories Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report

Which Regions Are Projected To Dominate The Humira Biosimilar Market In The Coming Years?

North America was the largest region in the humira biosimilar market in 2025. The regions covered in the humira biosimilar market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Humira Biosimilar Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp

Browse Through More Reports Similar to the Global Humira Biosimilar Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Humic Based Biostimulants Market Market Report 2026

https://www.thebusinessresearchcompany.com/report/humic-based-biostimulants-market-global-market-report

Biosimulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimulation-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795